Upper gastrointestinal (UGI) tolerability of valdecoxib, A Cox-2 specific inhibitor, compared with nonspecific (NS) NSAIDs among patients with osteoarthritis (OA) and rheumatoid arthritis (RA)

被引：1

|

作者：

Goldstein, JL

Eisen, GM

Hanna, DB

Burke, T

机构：

来源：

GASTROENTEROLOGY | 2003年 / 124卷 / 04期

关键词：

D O I：

10.1016/S0016-5085(03)82590-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：A511 / A512

页数：2

相关论文

共 37 条

[21] Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
Watson, DJ
Harper, SE
Zhao, PL
Quan, H
Bolognese, JA
Simon, TJ
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (19) : 2998 - 3003
[22] Valdecoxib provides similar efficacy and improved upper GI safety compared with naproxen in elderly and non-elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA).
Kivitz, A
Bensen, W
Makarowski, W
Bevirt, T
Riley, W
Recker, D
ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S160 - S160
[23] The gastrointestinal tolerability of a novel COX-2 selective inhibitor, lumiracoxib, in osteoarthritis patients: Pooled analysis
Hawkey, CJ
Gitton, X
Gimona, A
Hoexter, G
Weinstein, WM
GASTROENTEROLOGY, 2003, 124 (04) : A512 - A512
[24] Efficacy and safety of celecoxib, a specific COX-2 inhibitor in patients with rheumatoid arthritis
Geis, GS
Hubbard, RC
Callison, DA
Yu, S
Zhao, W
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (09) : S70 - S70
[25] Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis.
Geis, GS
Hubbard, R
Callison, D
Yu, S
Zhao, W
ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S364 - S364
[26] Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis.
Geis, GS
Stead, H
Morant, S
Naudin, R
Hubbard, R
ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S316 - S316
[27] Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis
Yun, HR
Bae, SC
RHEUMATOLOGY INTERNATIONAL, 2005, 25 (01) : 9 - 14
[28] Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis
Hyung Ran Yun
Sang-Cheol Bae
Rheumatology International, 2005, 25 : 9 - 14
[29] Evaluation of COX-2 Selective Inhibitor for the Protection of Intestinal Mucosal Damage in Comparison to NSAIDs in Patients With Rheumatoid Arthritis
Inoue, Takahiro
Iijima, Hideki
Mukai, Akira
Hayashi, Yoshito
Akasaka, Tomofumi
Kondo, Jumpei
Nakajima, Sachiko
Shinzaki, Shinichiro
Nishida, Tsutomu
Tsujii, Masahiko
GASTROENTEROLOGY, 2011, 140 (05) : S388 - S389
[30] Development of clinically significant systolic hypertension for the COX-2 selective inhibitor valdecoxib is similar to placebo and conventional NSAIDs in hypertensive patients with chronic arthritis
White, WB
Whelton, A
Pan, SX
Cheung, R
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 97A - 97A

← 1 2 3 4 →